Abstract:Absorbed dose profiles within tumor spheroids simulating avascular micrometastases have been calculated for a variety of liposome- and antibody-radionuclide combinations to assess the anticipated therapeutic efficacy based on the intratumoral distribution of the carrier systems within the spheroid model. Methods: Experiments studying the targeting and diffusion capability of the most clinically relevant liposome systems and the anti-PSMA (prostate-specific membrane antigen) antibody J591 within spheroids of the prostate cancer cell line LNCaP (diameter, 150-200 mum) have been performed. The intratumoral biodistribution data were then used as the input to obtain absorbed dose profiles within the tumor spheroid mass. The dosimetric analysis was performed for a variety of medium- and high-energy beta-emitting radionuclides ((32)P, (90)Y, (188)Re, (67)Cu, (131)I) and 2 low-energy Auger or conversion electron emitters ((123)I, (125)I) following the point-kernel convolution method in the continuous slowing-down approximation. Results: Relative absorbed dose distribution calculations as a function of the distance from the rim of the spheroids are presented. For all liposome systems studied, the SUV-DMPC-chol (small unilamellar vesicle-dimyristoyl-phosphatidylcholine-cholesterol) was most efficient in penetrating deeper within the spheroids. For the beta-emitters it delivered its maximum absorbed dose (D(max)) at 40- to 50-microm depth, exhibiting an almost flat absorbed dose profile beyond that point, as is evident by the high absorbed dose value at the center of the spheroid (D(core)), D(core)/D(max) > 0.9; the respective values for the J591 antibody were 20 mum and 0.85. The Auger or conversion emitters resulted in the most heterogeneous absorbed dose distribution; the ratio D(core)/D(max) fell to 0.4 for the SUV-DMPC-chol and to 0.4-0.5 for the antibody. In general, a 2- to 10-fold "cross-fire"-related increase of the core absorbed dose was observed. For liposomes exhibiting high binding capacity (3beta-[N-(N',N']-dimethylaminoethane)carbamoyl]cholesterol [DC-chol]), however, the low-energy emitters deliver up to a 40% higher D(max) relative to the beta-emitters. The surface characteristics of liposomes appear to have a noticeable influence on the absorbed dose profiles. The use of neutral (DMPC-chol) versus cationic (DC-chol) lipids resulted in up to a 10-fold increase of D(core)/D(max) depending on the radionuclide. Changing the cationic lipid used to N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate also had a notable influence (up to a 6-fold increase), whereas the effect of fusogenic lipids (dioleoylphosphatidylcholine) was found to be much smaller. Conclusion: It is possible to engineer liposome systems that are particularly effective in delivering an almost uniform absorbed dose profile at the central region of micrometastatic tumors, provided that conjugates with the appropriate radionuclides are constructed. In view of the passive means of diffusion of liposomes within solid tumors, it is suggested that they may effectively complement an antibody-based therapeutic regime against micrometastatic tumors, leading to cytotoxic absorbed dose levels throughout the entire tumor volume--thus, hindering tumor recurrence.

Experimental Study on Liposomal Drug Delivery System for Lymphatic Targeting

LyP-1-conjugated PEGylated Liposomes: a Carrier System for Targeted Therapy of Lymphatic Metastatic Tumor.

The Targeted-liposome Delivery System of Antitumor Drugs

Study on Tumor Targeting Ability of Neovessel-Targeted PEGylated Liposomes

Nanomaterial-Based Drug Delivery System Targeting Lymph Nodes

Passive and specific targeting of lymph nodes: the influence of the administration route

Impact of conjugation to different lipids on the lymphatic uptake and biodistribution of brush PEG polymers

Polymeric Micelles for Enhanced Lymphatic Drug Delivery to Treat Metastatic Tumors.

Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features

Roles of Dextrans on Improving Lymphatic Drainage for Liposomal Drug Delivery System.

The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution

Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody

Targeting Lymph Node Sinus Macrophages to Inhibit Lymph Node Metastasis

Multifunctional nanocarriers for targeted drug delivery and diagnostic applications of lymph nodes metastasis: a review of recent trends and future perspectives

Increased Tumor Targeted Delivery Using a Multistage Liposome System Functionalized with RGD, TAT and Cleavable PEG.

Potentiating Antilymphoma Efficacy of Chemotherapy Using A Liposome for Integration of Cd20 Targeting, Ultra-Violet Irradiation Polymerizing, and Controlled Drug Delivery

Advances in Liposomal Drug Delivery System in the Field of Chemotherapy

Organ-selective Lipid Nanoparticles for Precise Cancer Therapy: Beyond Liposomes and Polymeric Micelles

Preparation of a Novel Multifunctional Cationic Liposome Drug-carrying System and its Functional Study on Lung Cancer

Nanoparticle-based approaches to target the lymphatic system for antitumor treatment

Multiphysics-Informed Pharmacokinetic Modeling of Systemic Exposure of Intramuscularly Injected LNPs.